open access
The role of nesfatin and selected molecular factors in various types of endometrial cancer
- Department of Perinatology and Gynecology, Poznan University of Medical Sciences, Poznan, Poland
- Department of Oncology, Gynaecological Oncology, Poznan University of Medical Sciences, Poznan, Poland
- Department of Gynecology and Gynecologic Oncology, Medical University of Bialystok, Bialystok, Poland
- Department of Gyneacology and Obstetrics, Faculty of Health Science, Wroclaw Medical University, Wroclaw, Poland
- Medical School in Opole, Opole, Poland
- Department of Tumour Pathology and Prophylaxis, Poznan University of Medical Sciences, Greater Poland Cancer Centre, Poznan, Poland
- Medical University of Lodz, Gynecological-Oncology, Lodz, Poland
- Gynecological Endocrinology Department, Jagiellonian University Medical College, Krakow, Poland
open access
Abstract
Objectives: Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes and metabolic syndrome are among the biggest risk factors. Nesfatin-1, the adipokine derivative of NUCB2 (nucleobindin derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH1 and MHS2 genes, c-MET and ARID1A are also related to prognosis in endometrial cancer. Material and methods: Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of NESF1, MLH1, MSH2,c-MET and ARID1A were examined. Results: In this study on protein expression, EC tissues manifested (although insignificantly) an elevated expression of NESF-1 in type II EC. In type I EC, NESF-1 expression was significantly higher in G1 in comparison to G2 and G3 together. A significantly lower expression of MLH1 was demonstrated in type I EC. Conclusions: The most pronounced expression involved c-MET in all EC I and EC II tissues (in over 80% of cases). A tendency was detected for a high expression of NESF-1 in patients with type II EC, who also exhibited a high expression of MSH2.
Abstract
Objectives: Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes and metabolic syndrome are among the biggest risk factors. Nesfatin-1, the adipokine derivative of NUCB2 (nucleobindin derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH1 and MHS2 genes, c-MET and ARID1A are also related to prognosis in endometrial cancer. Material and methods: Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of NESF1, MLH1, MSH2,c-MET and ARID1A were examined. Results: In this study on protein expression, EC tissues manifested (although insignificantly) an elevated expression of NESF-1 in type II EC. In type I EC, NESF-1 expression was significantly higher in G1 in comparison to G2 and G3 together. A significantly lower expression of MLH1 was demonstrated in type I EC. Conclusions: The most pronounced expression involved c-MET in all EC I and EC II tissues (in over 80% of cases). A tendency was detected for a high expression of NESF-1 in patients with type II EC, who also exhibited a high expression of MSH2.
Keywords
endometrial cancer; NESF-1; MLH1; MSH2; c-MET; ARID1A
Title
The role of nesfatin and selected molecular factors in various types of endometrial cancer
Journal
Issue
Article type
Research paper
Pages
571-576
Published online
2019-10-31
Page views
1961
Article views/downloads
1438
DOI
Pubmed
Bibliographic record
Ginekol Pol 2019;90(10):571-576.
Keywords
endometrial cancer
NESF-1
MLH1
MSH2
c-MET
ARID1A
Authors
Anna Markowska
Monika Szarszewska
Pawel Knapp
Anna Grybos
Marian Grybos
Andrzej Marszalek
Violetta Filas
Katarzyna Wojcik-Krowiranda
Malgorzata Swornik
Janina Markowska
- Globocan 2012 Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr (16.01.2015).
- Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016; 26(1): 2–30.
- Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014; 15(7): e268–e278.
- Schmeler KM, Soliman PT, Sun CC, et al. Endometrial cancer in young, normal-weight women. Gynecol Oncol. 2005; 99(2): 388–392.
- Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1): 10–17.
- Setiawan VW, Yang HP, Pike MC, et al. Australian National Endometrial Cancer Study Group. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013; 31(20): 2607–2618.
- Cossio SL, Koehler-Santos P, Pessini SA, et al. Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil. Fam Cancer. 2010; 9(2): 131–139.
- Huang M, Djordjevic B, Yates MS, et al. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer. 2013; 119(16): 3027–3033.
- Attias-Geva Z, Bentov I, Kidron D, et al. p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy. Eur J Cancer. 2012; 48(10): 1570–1580.
- Togami S, Sasajima Y, Oi T, et al. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci. 2012; 103(5): 926–932.
- Bishop EA, Lengyel ER, Yamada SD, et al. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011; 121(1): 218–223.
- Bruchim I, Amichay K, Kidron D, et al. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer. 2010; 20(7): 1148–1153.
- Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013; 129(2): 277–284.
- Park JiY, Nam JH, Kim YT, et al. Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients. Virchows Arch. 2013; 462(3): 289–296.
- Kandoth C, Schultz N, Cherniack AD, et al. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67–73.
- Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 2017; 145(1): 200–207.
- Kreizman-Shefer H, Pricop J, Goldman S, et al. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagn Pathol. 2014; 9: 77.
- Sho T, Hachisuga T, Nguyen TT, et al. Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma. Int J Gynecol Cancer. 2014; 24(1): 102–106.
- Takeda T, Banno K, Okawa R, et al. ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncol Rep. 2016; 35(2): 607–613.
- Li M, Xin X, Wu T, et al. HGF and c-Met in pathogenesis of endometrial carcinoma. Front Biosci (Landmark Ed). 2015; 20(8): 635–643.
- Bischoff J, Ignatov A, Semczuk A, et al. hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis. 2012; 29(8): 889–900.
- Markowska A, Marszałek A, Szarszewska M, et al. Nesfatin-1 as a potential marker in endometrial and ovarian carcinomas. Post Biol Komórki. 2016; 43(3): 435–439.
- Takagi K, Miki Y, Tanaka S, et al. Nucleobindin 2 (NUCB2) in human endometrial carcinoma: a potent prognostic factor associated with cell proliferation and migration. Endocr J. 2016; 63(3): 287–299.
- Sasada S, Yunokawa M, Takehara Y, et al. Baseline risk of recurrence in stage I-II endometrial carcinoma. J Gynecol Oncol. 2018; 29(1): e9.
- Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med. 2005; 11(6): 284–292.
- Zhuang XP, Jin WW, Teng XD, et al. c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis. Eur J Gynaecol Oncol. 2015; 36(3): 255–259.
- Li M, Xin X, Wu T, et al. HGF and c-Met in pathogenesis of endometrial carcinoma. Front Biosci (Landmark Ed). 2015; 20(8): 635–643.
- Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009; 78: 273–304.
- Mao TL, Ardighieri L, Ayhan A, et al. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol. 2013; 37(9): 1342–1348.
- Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16): 1532–1543.
- Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011; 35(5): 625–632.